Altered oxidant-antioxidant status in non-obese men with moderate essential hypertension

H Nandeesha1, V Sathiyapriya, Zachariah Bobby

  • 1Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.

Insights

Early-stage hypertension in men shows an altered oxidant-antioxidant balance, with increased protein carbonyl and glutathione peroxidase, and decreased catalase and reduced glutathione. This suggests oxidative stress plays a role in hypertension development.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Oxidative Stress Research

Background:

  • Limited clinical data exists on oxidant-antioxidant imbalance in early-stage hypertension among men.
  • Experimental evidence suggests a link between oxidative stress and hypertension.

Purpose of the Study:

  • To investigate oxidative status and antioxidant enzyme activities in males diagnosed with stage I essential hypertension.
  • To compare biochemical markers of oxidative stress between hypertensive and normotensive men.

Main Methods:

  • Cross-sectional study involving 30 men with stage I essential hypertension and 21 normotensive controls.
  • Assessed plasma levels of protein carbonyl, reduced glutathione (GSH), glutathione peroxidase (GPx), catalase, and fasting glucose.
  • Statistical analysis included Student's t-test and linear regression.

Main Results:

  • Hypertensive men exhibited significantly elevated plasma protein carbonyl and GPx levels compared to normotensive controls.
  • Significantly reduced levels of catalase and GSH were observed in the hypertensive group.
  • A significant negative correlation was found between GPx and catalase in hypertensive subjects.

Conclusions:

  • Early-stage essential hypertension in non-obese men is associated with a distinct alteration in the oxidant-antioxidant status.
  • Findings suggest increased oxidative stress and compromised antioxidant defense mechanisms in the early phase of hypertension.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Oxidation of Phenols to Quinones01:17

Oxidation of Phenols to Quinones

In the presence of oxidizing agents, phenols are oxidized to quinones. Quinones can be easily reduced back to phenols using mild reducing agents. The electron-donating hydroxyl group enhances the reactivity of the aromatic ring, enabling oxidation of the ring even in the absence of an α hydrogen.
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox property is crucial in...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...